Background: Prostate cancer (PCa) is one of the most common cancers among men, yet little is known about its modifiable risk and protective factors. This study aims to quantitatively summarize observational studies relating physical activity (PA) to PCa incidence and mortality.
Introduction
Prostate cancer (PCa) is the second most frequent cancer among men worldwide, with an estimated 1.1 million new cancer cases diagnosed in 2012 [1] . Most of the cases are diagnosed in Australia/New Zealand, North America, and Europe, seemingly as a result of the practice of prostate-specific antigen (PSA) testing and biopsy investigations in more developed countries [1] .
Knowledge about risk factors of PCa is limited, complicating the formulation of appropriate strategies for the prevention of PCa. Advancing age, ethnicity, and a positive family history of PCa [2] are considered non-modifiable risk factors of PCa.
The role of potential modifiable risk factors for the development of PCa such as obesity, smoking, poor diet, and physical inactivity is less well understood [3] . Epidemiologic evidence suggests that physical activity (PA) may protect against certain malignancies, such as cancers of the colon, breast in postmenopausal women, and endometrium [4] . Whether there is an association between PA and PCa risk is not clear at this time.
A previous meta-analysis [5] showed an inverse association with PCa incidence for self-reported overall activity [summary relative risk (RR)¼0.90, 95% confidence interval (CI)¼0. 84-0.95] , recreational physical activity (RPA) (RR ¼ 0.95, 95% CI ¼ 0.89-1.00), and occupational physical activity (OPA) (RR ¼ 0.81, 95% CI ¼ 0.73-0.91) comparing the highest category of PA with the lowest. By comparison, a recent pooled analysis of data from seven prospective cohorts [6] reported statistically significant increased risks of total (HR ¼ 1.05, 95% CI ¼ 1.03-1.08) and non-advanced PCa (HR ¼ 1.08, 95% CI ¼ 1.03-1.12) associated with RPA, and a virtually null association for advanced PCa (HR ¼ 0.99, 95% CI ¼ 0.88-1.10).
The great heterogeneity of PCa which ranges from indolent to highly aggressive cancer may contribute to inconsistent results. Although indolent PCa is the most prevalent form of PCa, aggressive PCa is considered as the relevant clinical disease.
In order to resolve the remaining uncertainties about the PA and PCa relation, we conducted an up-to-date systematic review and meta-analysis of observational studies on PA and PCa incidence and mortality focusing on PCa subtype (e.g. advanced/aggressive PCa, non-advanced/non-aggressive PCa). We also carried out important subgroup analyses to determine whether the relation differs according to age, obesity, ethnicity, and PSA-testing. A further goal was to perform a dose-response meta-analysis to characterize the shape of the association between PA and PCa.
Methods

Participants, comparison, outcome, and study design
We quantitatively summarized data on PA and PCa incidence and mortality from cohort studies and case-control studies published between 1989 and 2017. Participants were males (mean age at baseline ¼ 61 years, mean age at diagnosis ¼ 69 years) providing self-reported information on PA. End points were overall PCa incidence, advanced and non-advanced PCa, and mortality from PCa ascertained by record linkage or self-report. Risk estimates were pooled comparing the highest versus the lowest study-specific categories of PA in relation to PCa incidence or mortality.
Systematic literature search
The present meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7] (supplementary Table S1 , available at Annals of Oncology online). Relevant articles were identified by searches of the Medline and EMBASE databases through 17 July 2017. The search terms for PA included motor activity/inactivity, sitting, sedentariness, sedentary lifestyle, exercise, walking, recreation, sport, athletes, endurance training, physical fitness/ training, and physical inactivity. We combined those search terms with terms for PCa including prostate/prostatic (neoplasm, tumor, cancer, carcinoma, and adenocarcinoma). The literature search was restricted to human studies that were published in English. In addition, we searched references of included articles.
Inclusion criteria
Studies were considered potentially eligible if they (i) were original cohort studies, nested case-control studies, or case-control studies; (ii) investigated the association between PA and PCa incidence or mortality; (iii) reported RRs, hazard ratios (HRs), standardized incidence rates (SIRs), or odds ratio (ORs) and 95% CIs; and (iv) were at least age-adjusted. For the dose-response analysis, studies were required to comprise at least three PA categories.
Data extraction and study quality assessment
The data were extracted by the principal reviewer (IB) and were double-checked by a second reviewer (DS). From each article, we extracted information regarding study characteristics, demographics of the participants, PA measures, and covariates for adjustment. Where possible, the risk estimates with their corresponding 95% CI from the most comprehensively adjusted model were used in the estimation of the summary RR.
The quality of each study was evaluated using the validated Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [8] (supplementary Table  S2 , available at Annals of Oncology online). That scale awards a maximum of nine points to each cohort study (four for quality of selection, two for comparability, and three for quality of outcome and adequacy of follow-up) and a score of nine points to each case-control study (four for quality of selection, two for comparability, and three for quality of exposure). Studies with an NOS score !6 (¼median) were classified as high quality studies and those with an NOS score <6 as low to moderate quality studies.
Statistical analysis
We interpreted effect estimates as RR estimates (RR i ) and computed the natural logarithms of those risk estimates log(RR i ) with corresponding standard error s i ¼d i /1.96, with d i representing the maximum of (log(upper 95% CI bound of RR i ) À log(RR i )) and ((log(RR i ) À log(lower 95% CI bound of RR i )). In randomeffects models, the log(RR i )s were weighted by w i ¼1/(s i 2 þt 2 ) where s i represented the standard error of log(RR i ) and t 2 the restricted maximum-likelihood estimate of the overall variance allowing for heterogeneity of effect measure. We used the Q-and I 2 -statistics to test for heterogeneity between risk estimates [9] . To evaluate potential publication bias, we employed Egger's regression test [10] , Begg's rank correlation test [11] , and a funnel plot.
Main meta-analysis of PA in relation to PCa incidence and mortality
The main meta-analysis included investigations of the relations of high versus low levels of PA to PCa according to PCa subtypes. PCa subtypes were defined by tumor stage and grade and were classified into non-aggressive/localized and aggressive/advanced PCa (supplementary Table S3 , available at Annals of Oncology online).
We prioritized risk estimates for overall recent PA. If studies did not provide information about overall PA, RPA or OPA was used. If studies provided risk estimates for different intensities of PA, we included risk estimates for vigorous intensity. Prioritizing moderate intensity or moderate to vigorous intensity did not change the results (data not shown).
We also included studies that examined the relation of prediagnosis PA to PCa mortality among individuals who were healthy at study entry. Furthermore, we included studies that investigated PA before and after diagnosis among PCa survivors in relation to PCa mortality.
Data were analyzed with the software R, version 3.0.1 using the packages 'metafor' and 'mvmeta'. The summary risk estimates are reported with 95% CIs and P values <0.05 were considered statistically significant.
Stratified meta-analyses of PA and PCa incidence
In the supplementary analyses, we used meta-regression models to examine potential differences according to number of subjects/ cases, study geographic location, study quality score, adjustments for positive family history of PCa, PSA testing or body mass index (BMI), mode and timing of PA assessment, PA intensity, and PA metric (e.g. MET-hours per week, times/week, minutes/day).
In further subgroup analyses, we examined whether the association between PA and PCa differed by age (adolescents, young adults, middle-aged adults, elderly), ethnicity (Whites, Blacks), BMI (<25, !25 kg/m 2 ), and recent PSA screening (yes, no). Three studies [12] [13] [14] provided separate risk estimates for the BMI categories 25-29.9 and !30 kg/m 2 . We pooled those values [12] [13] [14] using random-effects models to obtain a single risk estimate for the BMI category !25 kg/m 2 from each study. We included three studies in the BMI-stratified analysis that set the cut-off at a BMI of >25 kg/m 2 [12, 15] or 26 [16] .
Sensitivity analyses
To evaluate the potential influence of existing but undiagnosed disease (e.g. preclinical PCa) on the relation of PA to advanced PCa incidence or mortality, we further summarized data from studies that excluded individuals with diagnosis of advanced PCa in the first 3 [17] or 5 [18] years of follow-up, or updated exposure up to 4 [19] years before the event. Regarding PCa mortality, we summarized studies that excluded individuals who died within the first 18 [20] or 12 [21] months of follow-up, or that stopped updating exposures at the date of diagnosis [22] . To examine the robustness of our main analysis, we omitted one study at a time from the initial meta-analysis to evaluate whether a particular study may have influenced the summary risk estimate.
Dose-response meta-analysis of PA and PCa incidence
To identify a potential dose-response relation and to increase comparability between studies, we evaluated non-linear dose-response relations of overall and recreational activity to PCa incidence using first-and second-degree fractional polynomials [23] . Specifically, we fitted dose-response curves for activity duration (min/day), activity frequency (times/week), and activity energy expenditure (MET-hours/week) in relation to PCa incidence. Due to the limited number of studies, we were unable to perform a dose-response meta-analysis on PCa mortality.
Results
Literature search results and study
The results of the literature search and study selection process are presented in Figure 1 . The literature search yielded 4411 records identified in the electronic databases and 23 articles identified by reviewing references of published articles. After exclusion of reports identified in the databases more than once, 4191 publications remained for evaluation. After screening titles and abstracts, we excluded 4057 publications that were not original research articles on PA and PCa incidence or mortality. We further excluded 62 articles that provided information from the same study population [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , did not Records identified in electronic databases (n=4411)
Records identified in bibliographies (n= 23) Records removed that were presented in more than one database (n =243)
Titles and abstracts screened for potentially eligible studies (n =4191)
Full text articles assessed for eligibility (n=134)
Studies included in the meta-analysis (n=72)
48 cohort studies 24 case-control studies 4057 records excluded that were not related to physical activity and prostate cancer incidence or mortality 62 full-text articles excluded with
Sample derived from the same study population (n =20) Cross-sectional study (n=3) Case-control studies with cancer patients as control group (n=4) Inappropriate data (n= 19) Conference abstract (n = 12) No assessment of physical activity and prostate cancer incidence or mortality (n =2) Not adjusted for age or unknown adjustment (n =2) Figure 1 . Flow diagram of literature search and study selection.
assess the relationship between PA and PCa incidence or mortality [43, 44] , were conference abstracts [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] , had a crosssectional design [57] [58] [59] , considered cancer patients as control group [60] [61] [62] [63] , provided inappropriate data [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] (including one study that provided an inappropriate reference category [83] ) or did not adjust for age [84] . We excluded one study [85] that did not provide information about the covariates entered into the model. Publications with data from the same study population were included if the information could be used in different analyses. A total of 72 studies [6, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] met the inclusion criteria. Descriptive data from the studies included in our metaanalysis are shown in Table 1 . Forty-eight cohort studies and 24 case-control studies yielded data on 151 748 PCa cases. Fourteen studies investigated the relation of PA to advanced/aggressive and non-advanced/non-aggressive PCa. A total of 26 studies showed an NOS of <6 and 46 studies had an NOS of !6. In 43 and 21 studies, PA was assessed by self-administered questionnaire or interview, respectively, and PA was inferred from job titles in eight studies. The number of adjustment factors in the individual studies ranged from 1 to 21.
Main analysis
Our meta-analysis of PA and total PCa incidence (27 cohort studies and 23 case-control studies, 105 079 PCa cases) revealed a summary RR of 0.99 (95% CI ¼ 0.94-1.04) comparing the highest versus lowest category of PA (Figure 2 Figure 3) . In a supplementary analysis, we pooled risk estimates from studies that provided information on advanced, non-advanced, low-grade, or highgrade cancer (supplementary Figure S1 , available at Annals of Oncology online) and the results did not significantly differ. Our meta-analysis indicated a statistically significant between-study heterogeneity for all studies (I 2 ¼ 70%, P < 0.001), cohort studies (I 2 ¼ 68%, P < 0.001), and case-control studies (I 2 ¼ 79%, P < 0.001). Egger's regression test (P ¼ 0.04) and funnel plot (supplementary Figure S2 , available at Annals of Oncology online) inspection suggested the presence of publication bias, whereas Begg's correlation test did not (P ¼ 0.23).
In the meta-analysis stratified by domain, we excluded RPA studies that combined RPA with household chores. The summary RRs for RPA, OPA, and walking and/or biking in relation to total PCa incidence were 1.03 (95% CI ¼ 0.996-1.06, n ¼ 28), 0.91 (95% CI ¼ 0.82-1.01, n ¼ 26), and 0.91 (95% CI ¼ 0.81-1.02, n ¼ 5, P-difference for domain ¼ 0.001, Figure 4 ), respectively. Inclusion of studies that did not separate recreational activities from household chores did not essentially change the summary RR (RR ¼ 1.03, 95% CI ¼ 0.99-1.06). Only two studies [13, 92] A total of 14 cohort studies [18, 20-22, 87, 90, 101, 110, 114, 116, 128, 138, 139, 145] were included in the PA and PCa mortality meta-analysis ( Figure 5 ). The results indicated a summary RR of 0.93 (95% CI ¼ 0.81-1.08, n ¼ 10) for studies on pre-diagnosis PA and PCa mortality among healthy individuals (I 2 ¼59%, P ¼ 0.02). Two studies [128, 145] explored the relation of prediagnosis PA to PCa mortality among PCa survivors and showed a summary RR of 0.53 (95% CI ¼ 0.13-2.08). Summarizing four cohort studies [20, 21, 101, 145] that examined the association between PA after diagnosis and PCa mortality among PCa survivors yielded an RR of 0.69 (95% CI ¼ 0.55-0.85). One study [134] investigated the association between vigorous activity and progression of PCa and found a non-significant inverse association (HR ¼ 0.69, 95% CI ¼ 0.35-1.36).
Subanalyses
Twenty-two of the studies included in the main analysis adjusted for a positive family history of PCa and revealed a summary RR of 0.91 (95% CI ¼ 0.83-0.99), whereas the summary RR for studies that did not adjust for a positive family history was 1.04 (95% CI ¼ 0.97-1.11, P-difference ¼ 0.02). Stratification by PA intensity showed a P-difference of 0.02, with summary RRs of 0.89 (95% CI ¼ 0.75-1.04), 0.80 (95% CI ¼ 0.64-1.01), 1.04 (95% CI ¼ 1.01-1.09) and 1.01 (95% CI ¼ 0.94-1.08) for low, moderate, moderate to vigorous, and vigorous intensity PA, respectively.
We observed no statistically significant heterogeneity of the PA and PCa incidence relation according to other potential influential factors (all P-difference > 0.05, Table 2 , supplementary Figure S3 , available at Annals of Oncology online).
Sensitivity analyses
To account for potential reverse causation, three studies in our meta-analysis on PA and the incidence of advanced PCa Figure 2 . Forest plot corresponding to the relation of physical activity and total prostate cancer incidence across cohort studies and casecontrol studies. conducted secondary analyses in which they excluded individuals with 3 [17] or 5 years [18] of follow-up, or stopped updating exposure information 4 years before PCa diagnosis [19] . Summarizing the corresponding risk estimates revealed a summary RR of 0.61 (95% CI ¼ 0. 46-0.81 ). An additional two studies on post-diagnosis PA and PCa mortality among PCa survivors excluded the first 18 [20] or 12 [21] months of follow-up and the inverse association of the initial analysis was no longer statistically significant (summary RR ¼ 0.79, 95% CI ¼ 0.58-1.07).
Omission of one study at a time from the initial analysis of PA to total PCa did not substantially alter the results, with summary RRs ranging from 0.96 (95% CI ¼ 0.89-1.04, excluding Moore et al. [6] ) to 1.00 (95% CI ¼ 0.95-1.06, excluding Orsini et al. [116] ) for cohort studies and from 0. 95 Figure 5 . Forest plot corresponding to the relation of physical activity and prostate cancer mortality. Figure S4 , available at Annals of Oncology online).
Discussion
Our meta-analysis indicated insufficient evidence for a relation of overall PA to total PCa incidence, advanced/aggressive PCa, and non-advanced/non-aggressive PCa. However, long-term OPA was inversely related to total PCa incidence. Moreover, further stratification by PCa subtype revealed a statistically significant inverse association between long-term OPA and non-advanced PCa and a significant inverse association between long-term RPA and advanced PCa. These associations may represent an indication for a potential protective effect of long-term activity on PCa incidence. We had speculated that PA may reduce PCa risk through decreased body fat [146] , improved insulin sensitivity and insulin-like growth factor-1 (IGF-1) [147] , reduced levels of testosterone and dihydrotestosterone [148] , alterations in the antioxidant defense system [148] , and improvements in the immune system through enhanced natural killer cell activity [148] . For example, regular exercise has shown to reduce proliferation and to increase apoptosis of prostate tumor cells in vitro [147] . However, our findings must be interpreted with caution. First, our result on long-term OPA and total PCa incidence appeared to be affected by individual studies, rendering the previous inverse association statistically non-significant [116, 127] or borderline significant [86, 102, 117] after exclusion of each of those studies. Second, the results for advanced and non-advanced PCa stratified by activity domain and timing of PA are based on only two studies for each cancer subtype. RPA typically represents a more discontinuous form of vigorous activity which may be more difficultly recalled than OPA. OPA is normally moderate and of longer duration [86] , but most long-term OPA studies used job titles to assess OPA which may have introduced some degree of misclassification in our meta-analysis. Two studies [13, 92] reported on household PA and PCa incidence and found a positive association with PCa comparing the highest versus lowest levels of activity. Although the reason for the positive association between household activity and PCa incidence is unclear, this finding might reflect some degree of recall bias associated with this type of activity or residual confounding through insufficient adjustment for other risk factors in the models [13, 92] .
There are a number of potential reasons why we did not find a meaningful association between overall PA and total PCa incidence, if one existed.
Because PCa may have a long latent phase [149] , we have considered the possibility that we missed the induction period between PA exposure and the occurrence of PCa. We found that the findings for total PCa did not differ across timing in life of overall PA; however, we noted heterogeneous results for PCa subtype across different activity domains and timing of PA as discussed above. Giovannucci et al. [93] found that tallness, which may represent a surrogate for adolescent IGF-1 levels, was strongly positively related to mortality from PCa but not incidence, showing that further stratification by tumor stage may provide additional important insights into the PA and PCa relation across different time periods in life. Detection bias arising from PSA testing represents a further concern in our study. For example, physically active men may be more likely to have undergone PSA screening [6] and thus may be more likely to have an indolent cancer detected than physically inactive men. In our meta-analysis, the summary RR did not essentially differ between studies that adjusted for PSA testing and those that did not adjust for PSA testing. Two studies [12, 110] stratified their analysis according to whether men had a recent history of PSA examination or not and we found that the results did not essentially differ between the groups. Another study [93] investigated the relationship between PA and total PCa incidence according to PSA era and noted a positive association for PCa in the PSA era (HR ¼ 1.15, 95% CI ¼ 1.01-1.30) but not in the pre-PSA era (HR ¼ 0.95, 95% CI ¼ 0.74-1.22). In our meta-analysis, the subset of studies that adjusted for a positive family history of PCa noted a statistically significant inverse association of PA with PCa incidence, but no association was observed in studies that did not adjust for a positive family history. The reason for this observation is unclear, although it is possible that men having a positive family member with PCa are more likely to undergo PCa screening and to have PCa detected than those without a positive family history. Another consideration is that our findings may have resulted from measurement error due to self-report assessment of PA, which may have caused a certain degree of misclassification error. Finally, reverse causation is a potential concern in our study as men with metastatic disease may have had low PA levels due to symptoms or occult disease at the time of exposure assessment leading to a potentially spurious association between PA and PCa. In our meta-analysis on PA and PCa incidence, about 34% of the underlying cohort studies accounted for the potential effects of reverse causation in the sensitivity analyses by excluding cases that occurred in the first years of the follow-up period and reported that the individual results remained relatively unchanged. However, only three studies provided risk estimates of their sensitivity analyses [17] [18] [19] . Importantly, the summary RR of studies that excluded the first 3 [17] or 5 [18] years of followup, or updated exposure up to four years before the event [19] showed an inverse association between PA and advanced PCa suggesting that undiagnosed but existing PCa may have biased the association between PA and PCa incidence. Further studies are needed to confirm this finding. We have presented the first meta-analysis of studies relating to PA and PCa mortality. We noted a statistically non-significant inverse association with PCa mortality for pre-diagnosis PA among healthy individuals. Post-diagnosis PA was associated with a statistically significant 31% reduction in risk of PCa mortality among PCa survivors, although this observation must be interpreted with caution due to the limited number of studies. Moreover, the inverse association was no longer statistically significant after summarizing risk estimates from studies that accounted for potential reverse causation by excluding individuals with 18 or 12 months of follow-up.
PA may predispose to biologically less aggressive tumors [150] and may improve functional capacity [150] to tolerate and complete cancer treatment [150] , thereby slowing down cancer progression.
Our findings for the long-term OPA and total PCa incidence relation are in accordance with the findings from a previous meta-analysis [5] , whereas those for overall and recreational activity differ somewhat from that meta-analysis. Potential reasons for the different conclusions drawn by our meta-analysis may be the inclusion of a greater number of publications (72 articles versus 43 articles in Liu et al. [5] ) and the differences in inclusion criteria and prioritization of risk estimates. Moreover, we included the studies from a recent pooled analysis of data from seven cohort studies [6] showing statistically significant 5% and 8% increased risks of total and non-advanced PCa associated with RPA, whereas the relation was close to null for advanced PCa. The authors [6] reasoned that the observed positive associations of PA with total and non-advanced PCa may be partly explained by potential detection bias. The interpretation of our results is consistent with the World Cancer Research Fund International report 2014 [151] showing a summary RR of 0.97 (95% CI ¼ 0.90-1.04, based on 10 studies) for overall PA. The results of our dose-response analysis are in line with those of a recently published dose-response meta-analysis [152] reporting a null association between RPA and the incidence of PCa.
Our study has important strengths. Our comprehensive metaanalysis includes a considerable number of studies which enabled us to conduct numerous important subgroup analyses. Our meta-analysis differs from that by Liu et al. [5] in a number of important aspects. First, we extended our investigation to advanced and fatal PCa, which may represent a potentially important surrogate for clinically manifest PCa [90] . Second, we conducted a dose-response meta-analysis to explore the shape of the PA and PCa relation. We further summarized risk estimates according to the intensity and metric (e.g. MET-hours/week, minutes/day, times/week) of PA to increase the comparability between the risk estimates.
Several limitations of our study must be acknowledged. Caution is needed in interpreting the findings of our metaanalysis because of the difficulties arising from the heterogeneity between the underlying studies. The heterogeneous nature of PCa ranging from indolent to highly aggressive may partly have accounted for the inconsistent results in the underlying studies. As mentioned above, PA was assessed using self-report methods, which is known to pose a threat to the validity of the results [153] . The variability in the definition of high versus low levels of PA in the underlying studies further complicates interpretation of our findings.
The PA guidelines presented by the World Health Organization and the American College of Sports Medicine [154, 155] advocate that all adults engage in at least 150 min of moderate aerobic activity per week to improve their health. This PA recommendation also applies to cancer survivors [156] . Given the widely documented health benefits of regular PA, men including those affected by PCa are encouraged to reach for a physically active lifestyle.
Conclusions
Despite a growing body of literature on PA and PCa incidence, evidence for a link between overall PA and risk of PCa remains elusive. Our meta-analysis suggests that long-term OPA may protect against total PCa, although the results appear to vary by cancer subtype. Moreover, PA may improve PCa-specific survival among survivors of PCa. However, these findings should be interpreted with caution due to potential reverse causation and limited number of available studies. The role of PA as a protective factor for PCa requires further clarification. Moreover, the suggestive large benefit of PA after diagnosis on PCa mortality requires confirmation in future studies. In particular, future studies should consider the complex clinical and pathologic nature of PCa and the potential for reverse causation or detection bias owing to PSA testing.
